Archipel Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Archipel Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$4.5M	Buy	+40,098	New	+$3.82M	1.3%	25
2014 Q2	–	Sell	-107,268	Closed	-$7.59M	–	89
2014 Q1	$7.59M	Buy	+107,268	New	+$8.5M	1.96%	26

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Archipel Asset Management's VRTX Position: Q3 2014 in Review

Archipel Asset Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2014: 40,098 shares worth $4.5M. The stake represents 1.3% of the portfolio and ranks #25 among its holdings. This is a return to the name: Archipel Asset Management previously reported a position in VRTX as recently as Q1 2014.

Archipel Asset Management first reported a position in VRTX in Q1 2014 and has held it in 2 quarters since. The position peaked at $7.59M in Q1 2014. 430 funds tracked by Wall St. Rank hold VRTX as of Q3 2014.

Archipel Asset Management held 40,098 shares of Vertex Pharmaceuticals worth $4.5M as of Q3 2014.
Vertex Pharmaceuticals was a new Archipel Asset Management position in Q3 2014.
Vertex Pharmaceuticals made up 1.3% of Archipel Asset Management's portfolio in Q3 2014, its #25 holding.
Archipel Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2014 and has held it in 2 quarters since.
Archipel Asset Management's Vertex Pharmaceuticals position peaked at $7.59M in Q1 2014.
430 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2014.

Based on Archipel Asset Management's 13F filing for Q3 2014, filed 15 Oct 2014.